Aggarwal @docrota et al. TYK2/JAK1i brepoctinib in dermatomyositis. Supportive clinical and pharmacological evidence, plus efficacy of other JAK agents, likely to lead to a clinical trial. @rheumnow #ACR22 Abstr#0157
Brepocitinib for the Treatment of Dermatomyositis: Pharmacologic and Clinical Rationale - ACR Meeting Abstracts
